A clinical scoring system for congenital contractural arachnodactyly.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
01 2020
Historique:
received: 05 03 2019
accepted: 03 07 2019
pubmed: 19 7 2019
medline: 9 6 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Congenital contractural arachnodactyly (CCA) is an autosomal dominant connective tissue disorder manifesting joint contractures, arachnodactyly, crumpled ears, and kyphoscoliosis as main features. Due to its rarity, rather aspecific clinical presentation, and overlap with other conditions including Marfan syndrome, the diagnosis is challenging, but important for prognosis and clinical management. CCA is caused by pathogenic variants in FBN2, encoding fibrillin-2, but locus heterogeneity has been suggested. We designed a clinical scoring system and diagnostic criteria to support the diagnostic process and guide molecular genetic testing. In this retrospective study, we assessed 167 probands referred for FBN2 analysis and classified them into a FBN2-positive (n = 44) and FBN2-negative group (n = 123) following molecular analysis. We developed a 20-point weighted clinical scoring system based on the prevalence of ten main clinical characteristics of CCA in both groups. The total score was significantly different between the groups (P < 0.001) and was indicative for classifying patients into unlikely CCA (total score <7) and likely CCA (total score ≥7) groups. Our clinical score is helpful for clinical guidance for patients suspected to have CCA, and provides a quantitative tool for phenotyping in research settings.

Identifiants

pubmed: 31316167
doi: 10.1038/s41436-019-0609-8
pii: S1098-3600(21)01104-7
doi:

Substances chimiques

FBN2 protein, human 0
Fibrillin-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-131

Références

Hecht F, Beals RK. “New” syndrome of congenital contractural arachnodactyly originally described by Marfan in 1896. Pediatrics. 1972;49:574–579.
pubmed: 4552107
Ramos Arroyo MA, Weaver DD, Beals RK. Congenital contractural arachnodactyly. Report of four additional families and review of literature. Clin Genet. 1985;27:570–581.
doi: 10.1111/j.1399-0004.1985.tb02042.x
Viljoen D. Congenital contractural arachnodactyly (Beals syndrome). J Med Genet. 1994;31:640–643.
doi: 10.1136/jmg.31.8.640
Gupta PA, Putnam EA, Carmical SG, et al. Ten novel FBN2 mutations in congenital contractural arachnodactyly: delineation of the molecular pathogenesis and clinical phenotype. Hum Mutat. 2002;19:39–48.
doi: 10.1002/humu.10017
Callewaert BL, Loeys BL, Ficcadenti A, et al. Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: report of 14 novel mutations and review of the literature. Hum Mutat. 2009;30:334–341.
doi: 10.1002/humu.20854
Bamshad M, Jorde LB, Carey JC. A revised and extended classification of the distal arthrogryposes. Am J Med Genet. 1996;65:277–281.
doi: 10.1002/(SICI)1096-8628(19961111)65:4<277::AID-AJMG6>3.0.CO;2-M
Macnab AJ, D’Orsogna L, Cole DE, et al. Cardiac anomalies complicating congenital contractural arachnodactyly. Arch Dis Child. 1991;66:1143–1146.
doi: 10.1136/adc.66.10_Spec_No.1143
Gupta PA, Wallis DD, Chin TO, et al. FBN2 mutation associated with manifestations of Marfan syndrome and congenital contractural arachnodactyly. J Med Genet. 2004;41:e56.
doi: 10.1136/jmg.2003.012880
Takeda N, Morita H, Fujita D, et al. Congenital contractural arachnodactyly complicated with aortic dilatation and dissection: case report and review of literature. Am J Med Genet A. 2015;167a:2382–2387.
doi: 10.1002/ajmg.a.37162
Anderson RA, Koch S, Camerini-Otero RD. Cardiovascular findings in congenital contractural arachnodactyly: report of an affected kindred. Am J Med Genet. 1984;18:265–271.
doi: 10.1002/ajmg.1320180210
Bell RE, Wheller JJ. Cardiac defects in a patient with congenital contractural arachnodactyly. South Med J. 1985;78:742–743.
doi: 10.1097/00007611-198506000-00032
Huggon IC, Burke JP, Talbot JF. Contractural arachnodactyly with mitral regurgitation and iridodonesis. Arch Dis Child. 1990;65:317–319.
doi: 10.1136/adc.65.3.317
Su PH, Hou JW, Hwu WL, et al. Congenital contractural arachnodactyly (Beals syndrome). Acta Paediatr Taiwan. 2000;41:59–62.
pubmed: 10927940
Bass HN, Sparkes RS, Crandall BF, Marcy SM. Congenital contractural arachnodactyly, keratoconus, and probable Marfan syndrome in the same pedigree. J Pediatr. 1981;98:591–593.
doi: 10.1016/S0022-3476(81)80771-8
Bawle E, Quigg MH. Ectopia lentis and aortic root dilatation in congenital contractural arachnodactyly. Am J Med Genet. 1992;42:19–21.
doi: 10.1002/ajmg.1320420106
Tuncbilek E, Alanay Y. Congenital contractural arachnodactyly (Beals syndrome). Orphanet J Rare Dis. 2006;1:20.
doi: 10.1186/1750-1172-1-20
Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337–339.
doi: 10.1038/352337a0
Lee B, Godfrey M, Vitale E, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991;352:330–334.
doi: 10.1038/352330a0
Putnam EA, Zhang H, Ramirez F, Milewicz DM. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nat Genet. 1995;11:456–458.
doi: 10.1038/ng1295-456
Putnam EA, Cho M, Zinn AB, et al. Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. Am J Med Genet. 1996;62:233–242.
doi: 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U
Park ES, Putnam EA, Chitayat D, et al. Clustering of FBN2 mutations in patients with congenital contractural arachnodactyly indicates an important role of the domains encoded by exons 24 through 34 during human development. Am J Med Genet. 1998;78:350–355.
doi: 10.1002/(SICI)1096-8628(19980724)78:4<350::AID-AJMG9>3.0.CO;2-P
Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet. 2000;37:9–25.
doi: 10.1136/jmg.37.1.9
Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007;81:454–466.
doi: 10.1086/520125
Faivre L, Collod-Beroud G, Callewaert B, et al. Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation. Eur J Hum Genet. 2009;17:491–501.
doi: 10.1038/ejhg.2008.207
Nishimura A, Sakai H, Ikegawa S, et al. FBN2, FBN1, TGFBR1, and TGFBR2 analyses in congenital contractural arachnodactyly. Am J Med Genet A. 2007;143a:694–698.
doi: 10.1002/ajmg.a.31639
Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–315.
doi: 10.1038/ng.2892
Menten B, Buysse K, Vandesompele J, et al. Identification of an unbalanced X-autosome translocation by array CGH in a boy with a syndromic form of chondrodysplasia punctata brachytelephalangic type. Eur J Med Genet. 2005;48:301–309.
doi: 10.1016/j.ejmg.2005.04.014
Sante T, Vergult S, Volders PJ, et al. ViVar: a comprehensive platform for the analysis and visualization of structural genomic variation. PLoS ONE. 2014;9:e113800.
doi: 10.1371/journal.pone.0113800
Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356:331–333.
doi: 10.1056/NEJMp068282
Milewicz DM, Pyeritz RE, Crawford ES, Byers PH. Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. J Clin Invest. 1992;89:79–86.
doi: 10.1172/JCI115589
Dietz HC, McIntosh I, Sakai LY, et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics. 1993;17:468–475.
doi: 10.1006/geno.1993.1349
Eldadah ZA, Brenn T, Furthmayr H, Dietz HC. Expression of a mutant human fibrillin allele upon a normal human or murine genetic background recapitulates a Marfan cellular phenotype. J Clin Invest. 1995;95:874–880.
doi: 10.1172/JCI117737
Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet. 1995;4:1799–1809.
doi: 10.1093/hmg/4.suppl_1.1799
Milewicz DM, Urban Z, Boyd C. Genetic disorders of the elastic fiber system. Matrix Biol. 2000;19:471–480.
doi: 10.1016/S0945-053X(00)00099-8
Judge DP, Biery NJ, Keene DR, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004;114:172–181.
doi: 10.1172/JCI200420641
Dietz HC, Loeys B, Carta L, Ramirez F. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet. 2005;139c:4–9.
doi: 10.1002/ajmg.c.30068
Renard M, Francis C, Ghosh R, et al. Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2018;72:605–615.
doi: 10.1016/j.jacc.2018.04.089

Auteurs

Ilse Meerschaut (I)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Department of Pediatrics, Ghent University Hospital, Ghent, Belgium.

Shana De Coninck (S)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Wouter Steyaert (W)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Angela Barnicoat (A)

Department of Clinical Genetics, Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Allan Bayat (A)

Department of Pediatrics, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.

Francesco Benedicenti (F)

Clinical Genetics Service and South Tyrol Coordination Center for Rare Diseases, Department of Pediatrics, Regional Hospital of Bolzano, Bolzano, Italy.

Siren Berland (S)

Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.

Edward M Blair (EM)

Oxford Centre for Genomic Medicine, Oxford, UK.

Jeroen Breckpot (J)

Center for Human Genetics, University Hospitals Leuven, Catholic University Leuven, Leuven, Belgium.

Anna de Burca (A)

Oxford Centre for Genomic Medicine, Oxford, UK.

Anne Destrée (A)

Center for Human Genetics, Institute of Pathology and Genetics (IPG), Gosselies, Belgium.

Sixto García-Miñaúr (S)

Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, Madrid, Spain.

Andrew J Green (AJ)

Department of Clinical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland.
Department of Medicine and Medical Science, University College Dublin, Dublin, Ireland.

Bernadette C Hanna (BC)

Clinical Genetics Department, Westmead Hospital, Sydney, Australia.

Kathelijn Keymolen (K)

Centre for Medical Genetics, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.

Marije Koopmans (M)

Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.

Damien Lederer (D)

Center for Human Genetics, Institute of Pathology and Genetics (IPG), Gosselies, Belgium.

Melissa Lees (M)

Department of Clinical Genetics, Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Cheryl Longman (C)

West of Scotland Regional Genetics Service, Queen Elizabeth University Hospital, Glasgow, Scotland.

Sally Ann Lynch (SA)

Department of Clinical Genetics, Temple Street Children's Hospital, Dublin, Ireland.

Alison M Male (AM)

Department of Clinical Genetics, Great Ormond Street Hospital NHS Foundation Trust, London, UK.

Fiona McKenzie (F)

Genetic Services of Western Australia, Perth, WA, Australia.
School of Paediatrics and Child Health, University of Western Australia, Perth, WA, Australia.

Isabelle Migeotte (I)

Centre de Génétique Humaine, Université Libre de Bruxelles, Brussels, Belgium.

Ercan Mihci (E)

Department of Pediatric Genetics, Akdeniz University Medical School, Akdeniz, Turkey.

Banu Nur (B)

Department of Pediatric Genetics, Akdeniz University Medical School, Akdeniz, Turkey.

Florence Petit (F)

Clinique de Génétique, CHU Lille, Lille, France.

Juliette Piard (J)

Centre de Génétique Humaine, Université de Franche-Comté, CHU Besançon, Besançon, France.

Frank S Plasschaert (FS)

Department of Pediatric Orthopedics and Traumatology, Ghent University Hospital, Ghent, Belgium.

Anita Rauch (A)

Institut für Medizinische Genetik, Universität Zürich, Zürich, Switzerland.

Pascale Ribaï (P)

Center for Human Genetics, Institute of Pathology and Genetics (IPG), Gosselies, Belgium.

Iratxe Salcedo Pacheco (IS)

Pediatria, Alava iniversity hospital, Alava, Spain.

Franco Stanzial (F)

Clinical Genetics Service and South Tyrol Coordination Center for Rare Diseases, Department of Pediatrics, Regional Hospital of Bolzano, Bolzano, Italy.

Irene Stolte-Dijkstra (I)

Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Irene Valenzuela (I)

Department of Clinical and Molecular genetics and Rare disease Unit, University Hospital Vall d'Hebron, Barcelona, Spain.

Vinod Varghese (V)

Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.

Pradeep C Vasudevan (PC)

Medical Genetics, University of Leicester, University Hospitals of Leicester NHS Trust, Leicester, UK.

Emma Wakeling (E)

North West Thames Regional Genetics Service, London North West University Healthcare NHS Trust, Harrow, UK.

Carina Wallgren-Pettersson (C)

The Folkhaelsan Institute of Genetics and the Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.

Paul Coucke (P)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Anne De Paepe (A)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Daniël De Wolf (D)

Department of Pediatric Cardiology, Ghent University Hospital, Ghent, Belgium.

Sofie Symoens (S)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.

Bert Callewaert (B)

Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium. Bert.Callewaert@UGent.be.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH